Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6845-6852

  Mandic, Robert ^a   Schamberger, Chantal J ^b   Müller, Julia F ^a   Geyer, Matthias ^c   Zhu, Li ^a   Carey, Thomas E ^d   Grénman, Reidar ^e   Dünne, Anja A ^a   Werner, Jochen A ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; PROTEIN P53;

ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CARCINOMA CELL; CELL VIABILITY; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LASER MICROSCOPY; NUCLEAR LOCALIZATION SIGNAL; NUCLEOCYTOPLASMIC TRANSPORT; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLING; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; CLONING, MOLECULAR; COLORING AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, CONFOCAL; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; NUCLEAR LOCALIZATION SIGNALS; OPEN READING FRAMES; PROTEIN STRUCTURE, TERTIARY; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 26444448477     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0378     Document Type: Article

References (38)

1. 0 cancer of the pharynx and larynx. Br J Cancer 2002;87:711-5.
2. Werner JA, Rathcke IO, Mandic R. The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 2002;19:275-82.
3. DeLeo AB, Jay G. Appella E, et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979;76:2420-4.
4. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
5. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
6. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77.
7. Shaulsky G, Goldfinger N, Peled A, Rotter V. Involvement of wild-type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ 1991; 2:661-7.
8. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991;6:2055-65.
9. Addison C, Jenkins JR, Sturzbecher HW. The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene 1990;5:423-6.
10. Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem 2001;268:2779-83.
11. Liang SH, Clarke MF. A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem 1999;274: 32699-703.
12. Liang SH, Clarke MF, The nuclear import of p53 is determined by the presence of a basic domain and its relative position to the nuclear localization signal. Oncogene 1999;18:2163-6.
13. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003;282:59-69.
14. Middeler G, Zerf K, Jenovai S, et al. The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. Oncogene 1997;14:1407-17.
15. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
16. Bradford CR, Zhu S, Poore J, et al. p53 mutation as a prognostic marker in advanced laryngeal carcinoma. Department of Veterans Affairs Laryngeal Cancer Cooperative Study Group. Arch Otolaryngol Head Neck Surg 1997;123:605-9.
17. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25: 654-61.
18. Lansford C. Head and neck cancers. In: Masters J, editor. Human cell culture vol 2, cancer cell lines part 2. Dordrecht (Holland): Kluwer Academic Press; 1999. p. 185-255.
19. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 2003;22:4266-80.
20. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70:245-52.
21. Matlashewski GJ, Tuck S, Pim D, et al. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-3.
22. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265:346-55.
23. Fanucchi M, Khuri FR. Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol 2004;31:809-15.
24. Cerni C, Patocka K, Meneguzzi G. Immortalization of primary rat embryo cells by human papillomavirus type 11 DNA is enhanced upon cotransfer of ras. Virology 1990;177:427-36.
25. Austen M, Cerni C, Luscher-Firzlaff JM, Luscher B. YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene 1998;17:511-20.
26. Simonitsch I, Polgar D, Hajek M, et al. The cytoplasmic truncated receptor tyrosine kinase ALK homodimer immortalizes and cooperates with ras in cellular transformation. FASEB J 2001;15:1416-8.
27. Yamato K, Yamamoto M, Hirano Y, Tsuchida N. A human temperature-sensitive p53 mutant p53Val-138: modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene 1995;11:1-6.
28. Dry K, LegrosY, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994;13:3496-504.
29. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, Vere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002;51: 59-72.
30. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 1993;8:2555-9.
31. Calabretta B, Kaczmarek L, Selleri L, et al. Growth-dependent expression of human Mr 53,000 tumor antigen messenger RNA in normal and neoplastic cells. Cancer Resn 1986;46:5738-42.
32. Hamel N, Black MJ, Ghadirian P, Foulkes WD. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 2000;82:757-9.
33. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
34. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001;1:68-76.
35. Hauser U, Balz V, Carey TE, et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002;24:868-73.
36. Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 1994;13:3496-504.
37. Haupt S, Berger M, Goldberg Z. Haupt Y. Apoptosis-the p53 network. J Cell Sci 2003;116:4077-85.
38. Pekkola-Heino K, Servomaa K, Kiuru A, Grenman R. Sublethal damage repair capacity in carcinoma cell lines with p53 mutations. Head Neck 1998;20:298-303.